1
|
Leemans CR, Snijders PJF and Brakenhoff
RH: The molecular landscape of head and neck cancer. Nat Rev
Cancer. 18:269–282. 2018.PubMed/NCBI View Article : Google Scholar
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
3
|
Epstein MA and Barr YM: Cultivation in
vitro of human lymphoblasts from burkitt's malignant lymphoma.
Lancet. 1:252–253. 1964.PubMed/NCBI View Article : Google Scholar
|
4
|
Old LJ, Boyse EA, Oettgen HF, Harven ED,
Geering G, Williamson B and Clifford P: Precipitating antibody in
human serum to an antigen present in cultured burkitt's lymphoma
cells. Proc Natl Acad Sci USA. 56:1699–1704. 1966.PubMed/NCBI View Article : Google Scholar
|
5
|
de Schryver A, Friberg S Jr, Klein G,
Henle W, Henle G, De-Thé G, Clifford P and Ho HC: Epstein-Barr
virus-associated antibody patterns in carcinoma of the post-nasal
space. Clin Exp Immunol. 5:443–459. 1969.PubMed/NCBI
|
6
|
zur Hausen H, Schulte-Holthausen H, Klein
G, Henle W, Henle G, Clifford P and Santesson L: EBV DNA in
biopsies of Burkitt tumours and anaplastic carcinomas of the
nasopharynx. Nature. 228:1056–1058. 1970.PubMed/NCBI View Article : Google Scholar
|
7
|
Cao Y: EBV based cancer prevention and
therapy in nasopharyngeal carcinoma. NPJ Precis Oncol.
1(10)2017.PubMed/NCBI View Article : Google Scholar
|
8
|
Shahani T, Makvandi M, Samarbafzadeh A,
Teimoori A, Ranjbar N, saki N, Nikakhlagh S, Neisi N, Hosseini Z,
Pourrezaei S, et al: Frequency of Epstein Barr virus type 1 among
nasopharyngeal carcinomas in Iranian patients. Asian Pac J Cancer
Prev. 18:327–331. 2017.PubMed/NCBI View Article : Google Scholar
|
9
|
Young LS and Dawson CW: Epstein-Barr virus
and nasopharyngeal carcinoma. Chin J Cancer. 33:581–590. 2014.
|
10
|
Khan G and Hashim MJ: Global burden of
deaths from Epstein-Barr virus attributable malignancies 1990-2010.
Infect Agent Cancer. 9(38)2014.PubMed/NCBI View Article : Google Scholar
|
11
|
Varmus H and Kumar HS: Addressing the
growing international challenge of cancer: A multinational
perspective. Sci Transl Med. 5(175cm2)2013.PubMed/NCBI View Article : Google Scholar
|
12
|
Holmes D: The cancer-virus cures. Nat Med.
20:571–574. 2014.PubMed/NCBI View Article : Google Scholar
|
13
|
Lieberman PM: Virology. Epstein-Barr virus
turns 50. Science. 343:1323–1325. 2014.PubMed/NCBI View Article : Google Scholar
|
14
|
Tsao SW, Tsang CM and Lo KW: Epstein-Barr
virus infection and nasopharyngeal carcinoma. Philos Trans R Soc
Lond B Biol Sci. 372(20160270)2017.PubMed/NCBI View Article : Google Scholar
|
15
|
Sahoo R, Chittibabu V, Patil G, Rao S,
Thakur S, Dhondalay G, Kulkarni AJ, Banerjee A, Ajaikumar BS,
Korlimarla A, et al: Relationship between molecular markers and
treatment response in a retrospective cohort of Indian patients
with primary carcinoma of the larynx. Oral Oncol. 45:e216–e221.
2009.PubMed/NCBI View Article : Google Scholar
|
16
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014.PubMed/NCBI View
Article : Google Scholar
|
17
|
Kastenhuber ER and Lowe SW: Putting p53 in
Context. Cell. 170:1062–1078. 2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Wang Q, Lingel A, Geiser V, Kwapnoski Z
and Zhang L: Tumor suppressor p53 stimulates the expression of
epstein-barr virus latent membrane protein 1. J Virol.
91:e00312–17. 2017.PubMed/NCBI View Article : Google Scholar
|
19
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010.PubMed/NCBI View Article : Google Scholar
|
20
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011.PubMed/NCBI View Article : Google Scholar
|
21
|
Wenmei S, Yanming L, Fenping W, Hongsheng
G, Lixia L, Suwen Z, Zhennan L, Rong L and Zhixiong Y: Bcl-2
regulation by miR-429 in human nasopharyngeal carcinoma in vivo.
Int J Clin Exp Pathol. 9:5998–6006. 2016.
|
22
|
World Medical Association. World medical
association declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194.
2013.PubMed/NCBI View Article : Google Scholar
|
23
|
Kanno M, Narita N, Fujimoto Y, Wakisaka N,
Yoshizaki T, Kodaira T, Makita C, Sato Y, Yamazaki K, Wakaoka T, et
al: Third epidemiological analysis of nasopharyngeal carcinoma in
the central region of Japan from 2006 to 2015. Cancers (Basel).
11(1180)2019.PubMed/NCBI View Article : Google Scholar
|
24
|
Ngan HL, Wang L, Lo KW and Lui VWY:
Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs.
HPV-associated head and neck cancer. Cancers (Basel).
10(210)2018.PubMed/NCBI View Article : Google Scholar
|
25
|
Breda E, Catarino RJ, Azevedo I, Lobão M,
Monteiro E and Medeiros R: Epstein-Barr virus detection in
nasopharyngeal carcinoma: Implications in a low-risk area. Braz J
Otorhinolaryngol. 76:310–315. 2010.PubMed/NCBI
|
26
|
Al-Shidhani SNS, Al-Sinawi S, Al-Bahri M,
Al-Kindi M and Mabruk M: Determination of the expression of latent
Epstein Barr virus in Omani nasopharyngeal carcinoma patients.
Biomed Pharmacol J. 14:257–265. 2021.
|
27
|
Wu L, Li C and Pan L: Nasopharyngeal
carcinoma: A review of current updates. Exp Ther Med. 15:3687–3692.
2018.PubMed/NCBI View Article : Google Scholar
|
28
|
Yang HJ, Cho YJ, Kim HS, Chang MS, Sung MW
and Kim WH: Association of p53 and BCL-2 expression with
Epstein-Barr virus infection in the cancers of head and neck. Head
Neck. 23:629–636. 2001.PubMed/NCBI View
Article : Google Scholar
|
29
|
Sarac S, Akyol MU, Kanbur B, Poyraz A,
Akyol G, Yilmaz T and Sungur A: Bcl-2 and LMP1 expression in
nasopharyngeal carcinomas. Am J Otolaryngol. 22:377–382.
2001.PubMed/NCBI View Article : Google Scholar
|
30
|
Tulalamba W and Janvilisri T:
Nasopharyngeal carcinoma signaling pathway: An update on molecular
biomarkers. Int J Cell Biol. 2012(594681)2012.PubMed/NCBI View Article : Google Scholar
|
31
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013.PubMed/NCBI View
Article : Google Scholar
|
32
|
Tabyaoui I, Serhier Z, Sahraoui S, Sayd S,
Cadi R, Bennani OM, Benider A, Zamiati S and Tahiri JN:
Immunohistochemical expression of latent membrane protein 1 (LMP1)
and p53 in nasopharyngeal carcinoma: Moroccan experience. Afr
Health Sci. 13:710–717. 2013.PubMed/NCBI View Article : Google Scholar
|
33
|
Zhang P, Wu SK, Wang Y, Fan ZX, Li CR,
Feng M, Xu P, Wang WD and Lang JY: p53, MDM2, eIF4E and EGFR
expression in nasopharyngeal carcinoma and their correlation with
clinicopathological characteristics and prognosis: A retrospective
study. Oncol Lett. 9:113–118. 2015.PubMed/NCBI View Article : Google Scholar
|
34
|
Liu J, Liu Y, Zhang Z, Sun H, Ji X, Li B,
Zhou X and Gai P: Prognostic value of the Epstein-Barr virus and
tumor suppressor gene p53 gene in nasopharyngeal squamous cell
carcinoma. J Cancer Res Ther. 15:426–436. 2019.PubMed/NCBI View Article : Google Scholar
|
35
|
Menke DM, Griesser H, Moder KG, Tefferi A,
Luthra HS, Cohen MD, Colon-Otero G and Lloyd RV: Lymphomas in
patients with connective tissue disease. Comparison of p53 protein
expression and latent EBV infection in patients immunosuppressed
and not immunosuppressed with methotrexate. Am J Clin Pathol.
113:212–218. 2000.PubMed/NCBI View Article : Google Scholar
|
36
|
Niemhom S, Kitazawa S, Murao S, Kunachak S
and Maeda S: Co-expression of p53 and bcl-2 may correlate to the
presence of epstein-barr virus genome and the expression of
proliferating cell nuclear antigen in nasopharyngeal carcinoma.
Cancer Lett. 160:199–208. 2000.PubMed/NCBI View Article : Google Scholar
|
37
|
Chou J, Lin YC, Kim J, You L, Xu Z, He B
and Jablons DM: Nasopharyngeal carcinoma-review of the molecular
mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008.PubMed/NCBI View Article : Google Scholar
|
38
|
Allday MJ, Sinclair A, Parker G, Crawford
DH and Farrell PJ: Epstein-Barr virus efficiently immortalizes
human B cells without neutralizing the function of p53. EMBO J.
14:1382–1391. 1995.PubMed/NCBI
|
39
|
Belcher R, Hayes K, Fedewa S and Chen AY:
Current treatment of head and neck squamous cell cancer. J Surg
Oncol. 110:551–574. 2014.PubMed/NCBI View Article : Google Scholar
|
40
|
Perri F, Della Vittoria Scarpati G,
Buonerba C, Di Lorenzo G, Longo F, Muto P, Schiavone C, Sandomenico
F and Caponigro F: Combined chemo-radiotherapy in locally advanced
nasopharyngeal carcinomas. World J Clin Oncol. 4:47–51.
2013.PubMed/NCBI View Article : Google Scholar
|